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1436–8.When Is TAVR in Patients
With Severe Aortic
Stenosis Deemed Extreme
Risk for Surgery
Appropriate?Aortic stenosis is the most common valve disease and
is expected to rise because of an increase in life ex-
pectancy. Although physicians have learned how to
care for critically ill old patients and enable many to
survive major surgical procedures, operating on pa-
tients at very high risk is often not appropriate or
technically feasible.
Given these considerations, we read with much
interest the recent paper and editorial by Yakubov
et al. (1) and Pilgrim and Windecker (2), respectively,
in the Journal evaluating the 2-year outcomes after
transfemoral self-expanding transcatheter aortic
valve replacement in 489 extreme-risk patients. They
found that the rate of all-cause mortality or major
stroke was 39% at 2 years. The rates of all-cause
mortality, cardiovascular mortality, and major
stroke were 36.6%, 26.2%, and 5.1 %, respectively, at 2
years. The multivariable predictors of all-cause mor-
tality at 2 years included the presence of coronary
artery disease and admission from an assisted living
facility. In addition, at 2 years, 94% of patients had
New York Heart Association functional class I to IIsymptoms. A beneﬁt of this size is remarkable given
the extreme-risk patient population that has been
included.
However, it is concerning that 42% of patients who
died between year 1 and year 2 did so from non-
cardiovascular causes. Additionally, in a separate
study looking at health status in the CoreValve
Extreme Risk Group, the proportion of patients with a
poor outcome was 39% at 6 months (22% death, 16%
very poor quality of life, and 1.4% quality-of-life
decline). In similar studies looking at 5-year out-
comes for the inoperable group of the PARTNER IB
trial (Placement of Aortic Transcatheter Valve Trial),
48% had multiple readmissions in the ﬁrst year
(readmission rates were not reported in this study)
(3). These observations suggest that frail elderly pa-
tients often have competing risks contributing to
their all-cause mortality. To treat one disease process,
only for another to take its place, should not be the
objective of an invasive expensive treatment with
complications. The total life expectancy now sur-
passes the extra years of life lived in good health in
high-income nations, and this difference continues to
widen (4). This aging population of patients with
more comorbidities may be at risk for overtreatment.
Now that the safety and efﬁcacy of transcatheter
aortic valve replacement is established, the current
research efforts have to reorient to appropriate pa-
tient selection.*Femi Philip, MD
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